According to a report from the National Center for Biotechnology Information, cannabidiolic acid has been shown to inhibit MDA-MB-231, a powerful human breast cancer cell.

Another scientific study, another win for cannabis.

This isn’t the first we’ve heard of cannabidiol having a positive effect on the human body.

A report published by the Brazilian Journal of Medical and Biological research in 2006 showed how cannabidiol can be used to treat schizophrenia.

showed how cannabidiol can be used to treat schizophrenia.

In 2010 Neuropsychopharmacology showed that cannabidiol can be used to reduce THC’s memory loss effect.

showed that cannabidiol can be used to reduce THC’s memory loss effect.

Sativex, an oral spray consisting of tetrahydrocannabinol (THC) and cannabidiol (CBD), is marketed and sold in Canada to treat various ailments such as multiple sclerosis.

There may still be some of you who think getting high is a bad thing – have no fear! Cannabidiol isn’t psychoactive, so cannabidiolic acid won’t even get you high.

A study like this continues to undermine the United States’ understanding of cannabis, which is still a Schedule 1 drug. What classifies a drug as Schedule 1?

The drug or other substance has a high potential for abuse. The drug or other substance has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use of the drug or other substance under medical supervision.

Doesn’t sound like cannabis to me, and that’s a shame. This cannabidiolic acid could easily be used as a medical treatment, but the Schedule 1 placement will need to change before that can happen.